Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707678 | 0.80 | PTGS2 (0.36) | TAAR1ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL13263824 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2TAAR1HTTSMN1; SMN2 | |
| SCHEMBL3364100 | 0.79 | ESR1 (0.41) | GABRA1GABRB2TSHRTAAR1ALDH1A1 | |
| SCHEMBL28879956 | 0.79 | GABRA1 (0.43) | GABRA1GABRB2TSHRTAAR1ALDH1A1 | |
| SCHEMBL7322742 | 0.79 | GABRA1 (0.58) | GABRA1GABRB2TSHRTAAR1ALDH1A1 | |
| SCHEMBL166137 | 0.79 | TAAR1 (0.46) | GABRA1GABRB2TSHRTAAR1ALDH1A1 | |
| SCHEMBL29566515 | 0.79 | TAAR1 (0.46) | GABRA1GABRB2TSHRTAAR1ALDH1A1 | |
| SCHEMBL1849111 | 0.76 | GABRA1 (0.35) | GABRA1GABRB2TSHRTAAR1IDO1 | |
| SCHEMBL430886 | 0.76 | CA2 (0.43) | GABRA1GABRB2ALDH1A1MAPTHTT | |
| SCHEMBL4619300 | 0.76 | GABRA1 (0.45) | GABRA1GABRB2TSHRTAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702418-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4076418-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| WO-2021127429-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-3452476-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Holdings Corporation (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3365340-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017070089-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-2847174-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013151923-A1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-10 | — | — | WO | disclosed |
| EP-1888063-A1 | ANTIFUNGAL AGENTS | F2G Ltd. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006123145-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-1658288-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005014592-A1 | 2-AMINO-5-BENZOYLTHIAZOLE NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
| US-4417052-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; VIRICIDES | STERLING DRUG INC. (US) | 1983-11-22 | — | — | US | disclosed |
| US-4308382-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1981-12-29 | — | — | US | disclosed |
| US-4216326-A | Intermediates for preparing anti-inflammatory phenyl-lower-alkylamines | STERLING DRUG INC. (US) | 1980-08-05 | — | — | US | disclosed |
| US-4069256-A | Anti-inflammatory phenyl-lower-alkylamines | STERLING DRUG INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | GABRA1 3926/4885GABRB2 4067/4885TSHR 3618/4885 |
| US-11702418-B2 | SOS1 inhibitors | SOS1, SOS2, SOST | GABRA1 3926/4885GABRB2 4067/4885TSHR 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.